Sorafenib treatment has the potential to downstage advanced hepatocellular carcinoma before liver resection

Personalized Medicine
Alessandra BertaccoUmberto Cillo

Abstract

Sorafenib is acknowledged as the standard therapy for advanced hepatocellular carcinoma (HCC) but in the clinical practice the treatment of these patients is extremely complex and needs to be personalized. New evidence suggests that surgical resection-based multimodal treatments may improve outcome in these patients. There is no strong evidence supporting the ability of sorafenib in downstage HCC before surgery. We presented a case of a 53-year-old man with well-compensated HCV-cirrhosis complicated with HCC and neoplastic portal vein thrombosis. The patient was treated initially with sorafenib with optimal radiological and serological response and subsequently with liver resection. Pathological examination showed necrotic portal thrombosis and massive necrosis of a metastatic regional node confirming radiological evidence. This finding suggests that sorafenib exhibits a potential to downstage advanced HCC which is not irrelevant. A possible combination of different modalities has to be considered in the view of a personalized medicine.

References

Mar 22, 2002·The Lancet Oncology·D M Parkin
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Mar 10, 2012·Journal of Cancer Research and Clinical Oncology·Tian YangMeng-Chao Wu
Mar 20, 2012·Journal of Hepatology·UNKNOWN European Association For The Study Of The Liver, UNKNOWN European Organisation For Research And Treatment Of Cancer
May 29, 2012·Cell·Scott J DixonBrent R Stockwell
Mar 19, 2013·International Journal of Cancer. Journal International Du Cancer·Christophe LouandreAntoine Galmiche
Apr 5, 2013·World Journal of Gastrointestinal Oncology·Min Su KimMyoung Hun Chae
Aug 7, 2013·World Journal of Surgical Oncology·Sabrina Kermiche-RahaliMichel Scotté
Dec 15, 2015·Journal of Biomedical Optics·Johnny P SuGangjun Liu
Oct 19, 2016·Journal of Hepatology·Takashi KokudoUNKNOWN Liver Cancer Study Group of Japan
Jan 4, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard JacksonPhilip Johnson
Mar 23, 2017·Journal of Hepatology·Peter R GalleLuigi Bolondi
Jun 21, 2017·Clinical and Molecular Hepatology·Tae Suk KimKwan Soo Byun
Nov 22, 2017·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Edoardo Giovanni GianniniUNKNOWN Italian Liver Cancer (ITA.LI.CA) group
Jan 9, 2018·Lancet·Alejandro FornerJordi Bruix
Apr 10, 2018·Journal of Hepatology·UNKNOWN European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, UNKNOWN European Association for the Study of the Liver
May 28, 2019·Liver International : Official Journal of the International Association for the Study of the Liver·Alessandro VitaleUmberto Cillo
Jul 12, 2019·World Journal of Gastroenterology : WJG·Michael P Johnston, Salim I Khakoo

❮ Previous
Next ❯

Citations

Nov 3, 2020·Frontiers in Genetics·Huancheng Wang, Jia Liu
Apr 28, 2021·Annals of Surgical Oncology·Junichi ShindohMasaji Hashimoto

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection

Related Concepts

Related Feeds

Adrenocortical Carcinoma

Hepatocellular carcinoma is the most common type of primary liver cancer and frequently occurs in individuals with chronic liver diseases like cirrhosis. Here is the latest research.